Proposed LCD DL40427: MolDX: Next-Generation Sequencing for Hematologic Malignancies and Suspected Hematologic Malignancies — Noridian
Policy LCD-DL40427 · Oncology
Proposed LCD: NGS coverage for hematologic malignancies—comment by 10/11/26
Code intelligence
D46 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code D46.
Critical code riskView ICD-10 detail
Signal breakdown
5 shown · 5 total in platform
Risk: Critical
2
Critical
40%
1
High
20%
2
Routine
40%
0
Low
0%
New this month
+2
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Critical
Proposed LCD DL40425: MolDX: Next-Generation Sequencing for Hematologic Malignancies and Suspected Hematologic Malignancies — Palmetto GBA
Policy LCD-DL40425 · Oncology
Proposed LCD: NGS coverage criteria for blood cancers—comment by 10/11/26
LCD L36117: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease — CGS
Policy LCD-L36117 · Hematology
New genetic testing LCD affects billing for myeloproliferative disease.
LCD L39927: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative Neoplasms — Noridian
Policy LCD-L39927 · Hematology
New LCD for myeloproliferative neoplasm testing impacts billing.
LCD L36094: Lab: Flow Cytometry — Noridian
Policy LCD-L36094 · Clinical Laboratory
New LCD for Flow Cytometry affects lab billing practices.
Audit documentation
Building an audit file that includes D46?
The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Oncology audit pack — $349One-time purchase · not a subscription